The RNAi therapeutics and technologies market is anticipated to grow at a CAGR of 20%, till 2035, predicts Roots Analysis
The report features an extensive study of the current market landscape and the likely future potential, associated with the RNAi therapeutics market.
Considering the various advantages offered by RNAi over anti-sense based approaches and advances in delivery technologies, RNAi therapy offers the potential to revolutionize the biopharmaceutical industry, enabling the treatment of a wide range of diseases
The report features an extensive study of the current market landscape and the likely future potential, associated with the RNAi therapeutics market, over the next decade. The study also includes a detailed analysis of key drivers and trends within this evolving market.
Key companies covered in the report
· Alnylam Pharmaceuticals
· Dicerna Pharmaceuticals
· Gradalis
· Novartis
· Suzhou Ribo Life Sciences
· Sylentis
Amongst other elements, the report features:
§ A detailed overview of the overall market landscape of players engaged in the development of RNAi therapeutics.
§ A detailed overview of the players engaged in the development of RNAi therapeutics, based on year of establishment, company size, location of headquarters and regional landscape.
§ A competitive analysis of RNAi therapeutic developers, based on developer strength and product portfolio strength.
§ Elaborate profiles of drug candidates that are in the advanced stages of development (phase II / III and above).
§ An overview of the current market landscape of technology platforms available for the development of RNAi therapeutics, along with information on their developer, purpose of technology, type of molecule (s) delivered and type of cell (s) / tissue (s) targeted.
§ An insightful technology competitiveness analysis, benchmarking RNAi technologies, based on supplier power and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
§ A detailed analysis of the target indications that are currently the prime focus of companies engaged in the development of RNAi therapeutics.
§ An analysis of completed, ongoing and planned clinical studies evaluating the efficacy of RNAi therapeutics.
§ An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs engaged in this field.
§ An in-depth analysis of patents related to RNAi therapeutics, filed / granted, since 2016.
§ A detailed review of around 3,000 peer-reviewed, scientific articles related to research on RNAi therapeutics.
§ An analysis of the various partnerships related to RNAi therapeutics inked by players engaged in this domain.
§ A detailed analysis of various investments made by players engaged in this domain, during the period 2016-2021.
§ An elaborate discussion on the various commercialization strategies that can be adopted by drug developers engaged in this domain, across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing of the drug.
§ An elaborate discussion on the use of miRNA as a potential biomarker, along with a list of diagnostic kits that are either available in the market, or likely to be approved in the foreseen future.
§ A detailed analysis of the companies that are actively supporting the development of RNAi therapeutics market, including contract manufacturers, contract researcher organizations and other service providers.
§ An informed estimate of the annual demand for RNAi therapeutics.
§ A detailed analysis capturing affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the RNAi therapeutics market.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Key Therapeutic Areas
· Oncological Disorders
· Genetic Disorders
· Metabolic Disorders
· Hematological Disorders
· Ophthalmic Disorders
· Others
Routes of Administration
· Subcutaneous
· Intravenous
· Topical
· Intradermal
Types of RNAi Molecules
· siRNA
· shRNA
Key Geographical Regions
· North America
· Europe
· Asia-Pacific and the Rest of the World
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
